Developing a Natural History Progression Model for Duchenne Muscular Dystrophy using the Six Minute Walk Test.

The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve (2010) 2.78

Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn (2008) 2.50

The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve (2013) 2.47

Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes. PLoS One (2014) 2.43

Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol (2014) 2.15

North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord (2010) 2.14

Handling data below the limit of quantification in mixed effect models. AAPS J (2009) 2.11

Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology (2011) 2.06

The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations. Muscle Nerve (2010) 1.93

Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings. Clin Investig (Lond) (2011) 1.84

The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve (2013) 1.63

Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol (2016) 1.53

Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve (2014) 1.41

24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. PLoS One (2013) 1.34

The 6-minute walk test and person-reported outcomes in boys with duchenne muscular dystrophy and typically developing controls: longitudinal comparisons and clinically-meaningful changes over one year. PLoS Curr (2013) 1.28

Corticosteroids in Duchenne muscular dystrophy: major variations in practice. Muscle Nerve (2013) 1.20

Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids. Neuromuscul Disord (2013) 1.00

Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology (2015) 0.98

Six-minute walk test: reference values and prediction equation in healthy boys aged 5 to 12 years. PLoS One (2013) 0.97

The 6 minute walk test and performance of upper limb in ambulant duchenne muscular dystrophy boys. PLoS Curr (2014) 0.86

Duchenne Muscular Dystrophy: From Diagnosis to Therapy. Molecules (2015) 0.85

Reply. Ann Neurol (2017) 0.79

Comparing the performance of FOCE and different expectation-maximization methods in handling complex population physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn (2016) 0.78

Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy. Neuromuscul Disord (2016) 0.77